Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, placebo-controlled, double-blind study of the safety and immunogenicity of two injections of MVA3000 modified vaccinia ankara (MVA) smallpox vaccine in vaccinia naive adult subjects with a history of atopic dermatitis (AD)

Next Previous
X
Search
Trial Profile

A phase 1, placebo-controlled, double-blind study of the safety and immunogenicity of two injections of MVA3000 modified vaccinia ankara (MVA) smallpox vaccine in vaccinia naive adult subjects with a history of atopic dermatitis (AD)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MVA 3000 (Primary)
  • Indications Smallpox
  • Focus Adverse reactions
  • Sponsors Sanofi Pasteur

    • Most Recent Events

    • 17 Jan 2014 Planned End Date changed from 1 Sep 2007 to 1 Jan 2007 as per ClinicalTrials.gov record.
    • 07 Jan 2009 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
    • 22 Jun 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top